Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Diphencyprone for Cutaneous Neurofibromas in NF1
NCT05438290Phase 1Completed
- Start
- Sep 2022
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of diphencyprone in cutaneous neurofibroma (cNF). Primary endpoints: Proportion of subjects with a grade 3 adverse event at Day 107 and Symptom standardized assessment scale at Day 107. Started Sep 2022; status: completed.
02
Drugs
diphencyprone
03
Conditions
cutaneous neurofibroma (cNF)
Beyond the preview
Go deeper on NCT05438290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05438290.